Commenting on the results, Stephanie Hogue, Chief Executive Officer, said, "Our first quarter results reflect solid execution against the initiatives we laid out for 2026. We focused on driving ...
Phase 1 clinical data in patients with Parkinson’s disease demonstrating reduction in endolysosomal and neuroinflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results